Search Results

You are looking at 1 - 10 of 62 items for :

  • therapy resistance x
  • Open access x
Clear All
Open access

Simon Linder, Henk G van der Poel, Andries M Bergman, Wilbert Zwart, and Stefan Prekovic

approaches aimed to overcome therapy resistance (5). Figure 2 Graphical summary capturing the topics discussed in this review. Docetaxel has been the first agent showing a survival benefit in mCRPC patients (1). Despite initial responses upon docetaxel

Open access

Philipp Y Maximov, Balkees Abderrahman, Ramona F Curpan, Yousef M Hawsawi, Ping Fan, and V Craig Jordan

, Sledge et al . 2014 ). Here, we will address whether the lessons learned in breast cancer can be applied to prostate cancer therapy. Whether treatment strategies are the same or not for both diseases, resistance to antihormone treatments occurs in both

Open access

Jan Kroon, Martin Puhr, Jeroen T Buijs, Geertje van der Horst, Daniëlle M Hemmer, Koen A Marijt, Ming S Hwang, Motasim Masood, Stefan Grimm, Gert Storm, Josbert M Metselaar, Onno C Meijer, Zoran Culig, and Gabri van der Pluijm

of DEX has been described in preclinical ( Kroon et al . 2015 ) and clinical studies ( Venkitaraman et al . 2008 ). On the other hand, GC usage seems to be associated with the resistance to antiandrogen therapy ( Arora et al . 2013 , Isikbay et

Open access

Martina Gruber, Lavinia Ferrone, Martin Puhr, Frédéric R Santer, Tobias Furlan, Iris E Eder, Natalie Sampson, Georg Schäfer, Florian Handle, and Zoran Culig

, Kyriakopoulos et al. 2018 ). Additionally, docetaxel treatment has no negative consequences for subsequent endocrine therapies. Both abiraterone acetate and enzalutamide are used as effective second-line therapies after resistance to docetaxel has evolved

Open access

Su Jung Oh, Holger H H Erb, Alfred Hobisch, Frédéric R Santer, and Zoran Culig

, nonsteroidal antiandrogens (e.g. bicalutamide), or surgical castration. However, androgen-ablated tumors eventually develop resistance to this therapy and progress toward castration-resistant prostate cancer (CRPC), for which only palliative treatment is

Open access

Abigail Read and Rachael Natrajan

governs many aspects of cancer cell biology such as managing cellular proliferation, angiogenesis, resisting apoptosis, adapting cell metabolism, enhancing the ability to invade and metastasise and plays a role in resistance to cancer therapy ( David

Open access

Fabia De Oliveira Andrade, Wei Yu, Xiyuan Zhang, Elissa Carney, Rong Hu, Robert Clarke, Kevin FitzGerald, and Leena Hilakivi-Clarke

& Castiglione-Gertsch 2009 , Komm & Mirkin 2014 ). Unfortunately, resistance to endocrine therapies and consequent disease recurrence poses a major obstacle in the successful treatment of ER+ breast cancers. Recurrence often reflects transition to a more

Open access

Per Eystein Lønning and Hans Petter Eikesdal

findings from studies in the metastatic setting, revealing lack of cross-resistance between tamoxifen and aromatase inhibitors; thus, the idea was that switching from tamoxifen to an aromatase inhibitor during 5 years of adjuvant therapy may prevent

Open access

Bethany Smith, Priyanka Agarwal, and Neil A Bhowmick

tumor growth and potentiate therapy resistance ( Coulouarn et al . 2008 , Vonlaufen et al . 2008 , Duner et al . 2010 , Coulouarn & Clément 2014 ). However, due to the importance of the spatiotemporal nature of miR expression and action ( Sood et

Open access

John W Cassidy, Ankita S Batra, Wendy Greenwood, and Alejandra Bruna

patient-matched stromal cells, which can confer resistance to cytotoxic and targeted therapies ( Straussman et al. 2012 ). We, and others, have found that human stromal cells are replaced by murine equivalents upon engraftment in the mouse, suggesting